Adverum Biotechnologies Granted Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy
January 04, 2022 08:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022
December 21, 2021 08:00 ET
|
Adverum Biotechnologies, Inc.
- Finalizing Two-Dose Study Design for Phase 2 Trial of ADVM-022 in Wet AMDwith Intention to Dose First Patient in Q32022 - - Anticipates Near-term Hires to Further Strengthen Executive Team - -...
Adverum Biotechnologies Appoints Rupert D’Souza, Ph.D., M.B.A. as Chief Financial Officer
December 06, 2021 09:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Reports Third Quarter 2021 Results
November 04, 2021 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting
October 09, 2021 11:17 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Oct. 09, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile from Single Intravitreal Injection of ADVM-022 in Wet AMD Patients Who Previously Required Frequent Anti-VEGF Injections
October 01, 2021 16:00 ET
|
Adverum Biotechnologies, Inc.
-- Results featured in a presentation today at the Retina Society’s 54th Annual Scientific Meeting -- -- Robust aflibercept protein expression sustained through 2 years -- -- Over 80% reduction...
Adverum to Present Data from ADVM-022 Clinical Trials at Upcoming Medical Conferences
September 27, 2021 09:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...
Adverum Appoints Global Regulatory Leader Jim Wang, Ph.D., as Senior Vice President, Head of Regulatory Affairs
August 23, 2021 09:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Reports Second Quarter 2021 Results
August 05, 2021 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema
July 22, 2021 16:05 ET
|
Adverum Biotechnologies, Inc.
-- Based on latest analyses, company is revising ADVM-022 development plan to focus on wet AMD and low doses (2 x 10^11 vg/eye and lower); no longer planning development for DME -- -- Company to host...